Stephen L Swenson

US Patent:

20110300579, Dec 8, 2011

Filed:

Nov 12, 2009

Appl. No.:

13/127970

Inventors:

Radu O. Minea - Arcadia CA, US
Stephen D. Swenson - Arcadia CA, US

Assignee:

University of Southern California - Los Angeles CA

International Classification:

C12P 21/02
C12P 21/00

US Classification:

435 697

Abstract:

Provided herein are methods for expressing proteins with disulfide bridges such as Vicrostatin (VCN), a chimeric variant of native snake venom disintegrin Contortrostatin (CN). The methods include what is believed to be a more efficient natural selection process that results in generating increased amounts of correctly-folded active conformers of proteins with disulfide bridges. In an aspect, this is achieved by growing Origami B cells in a more optimal redox environment during the induction of heterologous recombinant protein production.

US Patent:

20120142603, Jun 7, 2012

Filed:

Feb 12, 2010

Appl. No.:

13/201433

Inventors:

Francis S. Markland - Manhattan Beach CA, US
Stephen D. Swenson - Arcadia CA, US
Radu O. Minea - Arcadia CA, US

International Classification:

A61K 38/02
C12N 5/0797
C12N 5/071

US Classification:

514 177, 514 208, 514 11, 435395

Abstract:

Provided herein are compositions and methods for treating soft tissue injuries using a patch having a polymer on its surface linked to polypeptides having a disintegrin domain. The polypeptides having a disintegrin domain can include contortrostatin, vicrostatin, and ADAM derived polypeptides. Compositions of the invention can be used for the treatment of injuries to soft tissues that include the eye, liver and brain.

US Patent:

20130177528, Jul 11, 2013

Filed:

Nov 12, 2012

Appl. No.:

13/674827

Inventors:

University of Southern California - Los Angeles CA, US
Western University of Health Sciences - Pomona CA, US
Stephen Swenson - Glendale CA, US
Vaibhav Tiwari - Pomona CA, US

Assignee:

WESTERN UNIVERSITY OF HEALTH SCIENCES - Pomona CA
UNIVERSITY OF SOUTHERN CALIFORNIA - Los Angeles CA

International Classification:

A61K 38/17
A61K 45/06
A61K 38/44
C12Q 1/02
A61K 38/48

US Classification:

424 854, 435375, 514 37, 424 9467, 424 944, 514 42, 4242041, 435 5, 530350, 435219

Abstract:

Provided herein are compositions and methods for inhibiting viral infection of a host cell. The methods comprise contacting the the host cell with an effective amount of one or more polypeptides having a disintegrin domain. The polypeptide can be CN, VCN or modified ADAM-derived polypeptide (MAP), or a fusion protein comprising a CN, VCN or MAP.

US Patent:

59519819, Sep 14, 1999

Filed:

Dec 2, 1996

Appl. No.:

8/753781

Inventors:

Francis S. Markland - Manhattan Beach CA
Larry R. Bush - Exeter NH
Stephen Swenson - Arcadia CA
Eladio Flores Sanchez - Belo Horizonte-ma, BR

Assignee:

Diatide, Inc. - Londonderry NH

International Classification:

A61K 3854
A61K 3846
C12N 996
C12N 948

US Classification:

424 9467

Abstract:

This invention provides thrombolytic agents and methods for making and using thrombolytic agents. Specifically, the invention provides thrombolytic agents comprising a thrombolytic proteinase and a specific binding peptide that specifically binds at the site of blood clots and thrombi in vivo. The invention particularly provides chemically crosslinked conjugates of a thrombolytic proteinase and a plurality of specific binding peptide. Methods for producing such chemically crosslinked conjugates and methods for using such conjugates for eliminating thrombi in vivo to alleviate pathological conditions caused thereby are also provided. The preferred thrombolytic proteinase in the conjugate is fibrolase obtainable from Agkistrodon contortrix confortrix venom.

US Patent:

62145940, Apr 10, 2001

Filed:

May 6, 1999

Appl. No.:

9/306150

Inventors:

Francis S. Markland - Manhattan Beach CA
Stephen D. Swenson - Arcadia CA

Assignee:

University of California - Los Angeles CA

International Classification:

C12N 1106
C12N 1110
C12N 1112
C12N 1108
C12N 996
C12N 948

US Classification:

435181

Abstract:

A size modified fibrinolytic enzyme, wherein the size of the enzyme is modified by covalent attachment of at least one large organic molecule to the enzyme.

US Patent:

20180353627, Dec 13, 2018

Filed:

Nov 11, 2016

Appl. No.:

15/775743

Inventors:

- Los Angeles CA, US
Francis S. Markland - Los Angeles CA, US
Radu O. Minea - Los Angeles CA, US
Stephen D. Swenson - Los Angeles CA, US

International Classification:

A61K 51/08
A61K 38/17
A61P 35/00

Abstract:

A method for suppressing or inhibiting the growth of a cancer cell or tumor cell that expresses one or more integrins on its cell surface in a subject in need thereof is disclosed, herein, the method comprising administering to the subject an effective amount of contortrostatin (CN) and/or vicrostatin (VCN) or an equivalent of each thereof and wherein the CN and/or VCN or the equivalent of each thereof is conjugated to a therapeutic radioisotope.

US Patent:

20160317610, Nov 3, 2016

Filed:

Sep 25, 2014

Appl. No.:

15/080401

Inventors:

Stephen D. Swenson - Glendale CA, US
Radu O. Minea - Arcadia CA, US

Assignee:

University of Southern California - Los Angeles CA

International Classification:

A61K 38/16
A61K 45/06

Abstract:

A method of treating ovarian cancer (OC) includes administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising vicrostatin and/or a protein substantially similar to vicrostatin. The administration is preferably performed intraperitoneally. The methods may include concurrently or sequentially administering to the patient one or more additional treatments for ovarian cancer. A pharmaceutical composition used in connection with the methods of the present invention comprise vicrostatin loaded in a viscoelastic gel comprising polyethylene oxide (PEO) and carboxymethyl cellulose (CMC).